These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 6393400)
1. Hormone receptors. An update and application. Hubay CA; Arafah B; Gordon NH; Guyton SP; Crowe JP Surg Clin North Am; 1984 Dec; 64(6):1155-72. PubMed ID: 6393400 [TBL] [Abstract][Full Text] [Related]
2. Ludwig Breast Cancer trial LBCS III: chemo- and endocrine adjuvant treatment in postmenopausal patients. Gelber RD Recent Results Cancer Res; 1984; 96():102-9. PubMed ID: 6396763 [No Abstract] [Full Text] [Related]
3. Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer. Pearson OH; Hubay CA; Gordon NH; Marshall JS; Crowe JP; Arafah BM; McGuire W Cancer; 1989 Nov; 64(9):1819-23. PubMed ID: 2790695 [TBL] [Abstract][Full Text] [Related]
4. Chemo- or endocrine adjuvant therapy alone or combined in postmenopausal patients (GABG Trial 1). Jonat W; Kaufmann M; Abel U Recent Results Cancer Res; 1989; 115():163-9. PubMed ID: 2696028 [No Abstract] [Full Text] [Related]
5. Ludwig Breast Cancer trials LBCS III and IV: adjuvant endocrine treatment in postmenopausal patients. Goldhirsch A Recent Results Cancer Res; 1984; 96():204-9. PubMed ID: 6549355 [No Abstract] [Full Text] [Related]
6. Adjuvant chemo- and endocrine therapy alone or in combination in premenopausal patients (GABG Trial 1). Kaufmann M; Jonat W; Abel U Recent Results Cancer Res; 1989; 115():118-25. PubMed ID: 2696024 [No Abstract] [Full Text] [Related]
7. Adjuvant systemic therapy in postoperative node-positive patients with breast carcinoma: the CALGB trial and the ECOG premenopausal trial. Tormey C Recent Results Cancer Res; 1984; 96():155-65. PubMed ID: 6396769 [No Abstract] [Full Text] [Related]
8. Adjuvant systemic treatment of resectable breast cancer: eleven years results of a monoinstitutional chemo-hormone-immunotherapy trial. Rosso R; Boccardo F; Brema F; Sertoli MR; Amoroso D; Bertelli G; Pronzato P Anticancer Res; 1989; 9(4):1153-6. PubMed ID: 2817796 [TBL] [Abstract][Full Text] [Related]
9. Significant survival benefit of node-negative breast cancer patients treated with adjuvant chemotherapy: seven-year results. Jakesz R; Reiner G; Schemper M; Reiner A; Blijham G; Rainer H; Dittrich D; Spona J; Schutte B; Reynders M Recent Results Cancer Res; 1989; 115():180-5. PubMed ID: 2696031 [No Abstract] [Full Text] [Related]
10. Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients. Mouridsen HT; Rose C; Brincker H; Thorpe SM; Rank F; Fischerman K; Andersen KW Recent Results Cancer Res; 1984; 96():117-28. PubMed ID: 6396765 [No Abstract] [Full Text] [Related]
11. Adjuvant chemotherapy of breast cancer: a promising experiment or standard practice? Henderson IC J Clin Oncol; 1985 Feb; 3(2):140-3. PubMed ID: 3881560 [No Abstract] [Full Text] [Related]
12. Adjuvant chemo-endocrine therapy or endocrine therapy alone for postmenopausal patients: Ludwig Studies III and IV. Goldhirsch A; Gelber RD Recent Results Cancer Res; 1989; 115():153-62. PubMed ID: 2696027 [No Abstract] [Full Text] [Related]
13. Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer: seventy-two-month follow-up. Hubay CA; Gordon NH; Crowe JP; Guyton SP; Pearson OH; Marshall JS; Mansour EG; Hermann RE; Jones JC; Flynn WJ Surgery; 1984 Jul; 96(1):61-72. PubMed ID: 6740497 [TBL] [Abstract][Full Text] [Related]
14. Tamoxifen and combination chemotherapy as adjuvant treatment in postmenopausal women with breast cancer. Wallgren A; Baral E; Beling U; Carstensen J; Friberg S; Glas U; Kaigas M; Skoog L Recent Results Cancer Res; 1984; 96():197-203. PubMed ID: 6396775 [No Abstract] [Full Text] [Related]
15. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391 [TBL] [Abstract][Full Text] [Related]
16. Scottish adjuvant breast cancer trials: results in pre-menopausal patients. Stewart HJ Recent Results Cancer Res; 1989; 115():126-31. PubMed ID: 2696025 [No Abstract] [Full Text] [Related]
17. Adjuvant chemotherapy for node-negative breast cancer patients. Bonadonna G; Zambetti M; Valagussa P Recent Results Cancer Res; 1989; 115():175-9. PubMed ID: 2516350 [No Abstract] [Full Text] [Related]
18. Adjuvant programs for postmenopausal women with node-positive breast cancer: preliminary analysis of 5-year results. Rossi A; Brambilla C; Valagussa P; Bonadonna G Recent Results Cancer Res; 1984; 96():178-83. PubMed ID: 6396772 [No Abstract] [Full Text] [Related]
19. Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status. Rivkin SE; Knight WA; McDivitt R; Cruz T; Foulkes M; Osborne CK; Fabian CJ; Costanzi JJ World J Surg; 1985 Oct; 9(5):723-7. PubMed ID: 3840629 [No Abstract] [Full Text] [Related]
20. Adjuvant systemic therapy in primary breast cancer. Mouridsen HT; Palshof T Acta Chir Scand Suppl; 1984; 519():43-53. PubMed ID: 6393664 [No Abstract] [Full Text] [Related] [Next] [New Search]